Schott Pharma AG KGaAWBO:1SXP +2.98%61 Operating Margin % is 15.95% as of Mar. 2026, which is 16% below its 10-year median of 18.99. GuruFocus rates WBO:1SXP with a GF Score™ of 61/100 and a GF Value™ of €28.06 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Schott Pharma AG KGaA ranks better than 82.97% on this metric.
Schott Pharma AG & CO KGaA operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for Schott Pharma AG KGaA's Operating Margin % or its related term are showing as below:
WBO:1SXP'
s Operating Margin % Range Over the Past 10 Years
Min: 15.68 Med: 18.99 Max: 20.62
Current: 18.15
WBO:1SXP's Operating Margin % is ranked better than 82.97% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: 3.465
vs WBO:1SXP: 18.15
Schott Pharma AG KGaA's 5-Year Average Operating Margin % Growth Rate was 3.50% per year.
Schott Pharma AG KGaA (WBO:1SXP) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Schott Pharma AG KGaA Operating Margin % Related Terms
Schott Pharma AG KGaA Operating Margin % Historical Data
* Premium members only.
The historical data trend for Schott Pharma AG KGaA's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:1SXP vs ISRG, BDX, MDLN: Operating Margin % Comparison
For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Schott Pharma AG KGaA Operating Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Schott Pharma AG KGaA's Operating Margin % falls into.
Schott Pharma AG KGaA Operating Margin % Calculation
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Schott Pharma AG KGaA's Operating Margin % for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Schott Pharma AG KGaA (WBO:1SXP) has a Operating Margin % of 15.95% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Schott Pharma AG KGaA and its competitors. This is 16% below median its historical median of 18.99. Over the past decade, Schott Pharma AG KGaA's Operating Margin % has ranged from 15.68 to 20.62. According to the industry distribution chart, Schott Pharma AG KGaA ranks #139 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 17%.
Is Schott Pharma AG KGaA's Operating Margin % too high?
Schott Pharma AG KGaA's current Operating Margin % of 15.95% is 16% below median its 10-year median of 18.99. Over the past 10 years, this metric has ranged from a low of 15.68 to a high of 20.62. The Medical Devices & Instruments industry median Operating Margin % is 3.47. Schott Pharma AG KGaA's value of 15.95% is 360.3% above this industry median. Based on the distribution chart, Schott Pharma AG KGaA ranks #139 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Schott Pharma AG KGaA has a GF Score™ of 61/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's Operating Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Schott Pharma AG KGaA ranks #139 out of 816 companies for Operating Margin %. This places Schott Pharma AG KGaA in the top 17% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 3.47. Schott Pharma AG KGaA's value of 15.95% is 360.3% above this benchmark. Historically, Schott Pharma AG KGaA's own Operating Margin % has ranged from 15.68 to 20.62 over the past decade. While the company's 10-year median is 18.99 vs. the industry median of 3.47, Schott Pharma AG KGaA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Devices & Instruments company?
The median Operating Margin % among Medical Devices & Instruments companies is 3.47, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Schott Pharma AG KGaA's current Operating Margin % of 15.95% is 360.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Schott Pharma AG KGaA and its competitors. For the Medical Devices & Instruments industry, the median Operating Margin % is 3.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Schott Pharma AG KGaA's current Operating Margin % is 15.95%, which is 16% below median its own 10-year median of 18.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Based on GuruFocus' analysis, Schott Pharma AG KGaA (WBO:1SXP) is currently considered Significantly Undervalued. The stock's GF Value™ is €28.06, compared to a current price of €17.30 — trading 38.3% below its estimated fair value. The current Operating Margin % is 15.95%, which is 16% below median its 10-year median of 18.99 and 360.3% above the Medical Devices & Instruments industry median of 3.47. Schott Pharma AG KGaA's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Schott Pharma AG KGaA (WBO:1SXP), the current Operating Margin % is 15.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Schott Pharma AG KGaA (WBO:1SXP) Overvalued in 2026?
Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued.
The current stock price of €17.30 is trading 38.3% below its estimated GF Value™ of €28.06.
GuruFocus considers Schott Pharma AG KGaA to be Significantly Undervalued.
Key valuation signals for WBO:1SXP:
Operating Margin %: 15.95% (16% below median its 10-year median of 18.99)
GF Value™: €28.06 vs. price of €17.30 (38.3% below fair value)
Industry Position: 360.3% above the Medical Devices & Instruments median (#139 of 816)
No single metric tells the full story. See the WBO:1SXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
61GF Score
Get the complete analysis for WBO:1SXP
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:1SXP has been successfully added to your 
